首页 > 最新文献

Revista espanola de medicina nuclear e imagen molecular最新文献

英文 中文
Radiosynoviorthesis with [90Y] Yttrium citrate in refractory synovitis of the knee: Experience of 2 reference hospitals 用[90Y]枸橼酸钇进行放射综合治疗难治性膝关节滑膜炎:两家参考医院的经验。
Pub Date : 2024-11-01 DOI: 10.1016/j.remnie.2024.500052
I. Bolívar Roldán , Ana Moreno Ballesteros , C. Martínez Chinchilla , A. Jiménez-Heffernan , M.C. Calvo Morón

Introduction

To describe the therapeutic efficacy of radiosynoviorthesis with [90Y]Yttrium citrate (90Y), in patients with chronic knee synovitis refractory to systemic treatments and/or infiltrations, correlating the results with the different etiologies and degenerative changes that they showed, in order to optimize the indication of the technique.

Material and methods

Observational retrospective study with 32 patients (22 men and 10 women) and 34 knees, with refractory chronic knee synovitis, who underwent radiosynoviorthesis between January 2013 and December 2022. Its efficacy was described and analyzed by the subjective improvement referred by the patients and its relationship with the existing etiologies and radiological degenerative changes, expressed by the Kellgren-Lawrence (K-L) scale.

Results

A statistically significant subjective improvement was observed in 70.6% of the cases (p < 0.001). There were 92.3% of cases with absent, doubtful or mild degenerative changes (K-L 0-2) who improved, while only 50% with moderate or severe changes (K-L 3-4) improved, showing statistically significant differences (p = 0.03). Among patients with chronic inflammatory origin of synovitis (spondyloarthropathies and rheumatoid arthritis), 80% improved, while in those with osteoarthritis (degenerative) origin, only 25% improved with statistically significant differences (p = 0.006).

Conclusions

Radiosynoviorthesis with 90Y is an effective treatment in patients with knee refractory chronic synovitis, especially in the presence of mil degenerative joint changes and chronic inflammatory origin. We must ensure the appropiate selection of patients according to these criteria.
简介目的:描述[90Y]枸橼酸钇(90Y)放射ynoviorthesis对全身治疗和/或浸润难治性慢性膝关节滑膜炎患者的疗效,并将结果与不同病因和退行性病变相关联,以优化该技术的适应症:观察性回顾研究:在2013年1月至2022年12月期间,对32名难治性慢性膝关节滑膜炎患者(22名男性和10名女性)和34个膝关节进行了放射性滑膜炎治疗。根据患者的主观改善情况及其与现有病因和放射学退行性病变的关系(用凯尔格伦-劳伦斯(K-L)量表表示)对其疗效进行了描述和分析:结果:在 70.6% 的病例中观察到明显的主观改善(P. 结论):对于膝关节难治性慢性滑膜炎患者,尤其是存在关节退行性病变和慢性炎症的患者,90Y 放射免疫术是一种有效的治疗方法。我们必须确保根据这些标准适当选择患者。
{"title":"Radiosynoviorthesis with [90Y] Yttrium citrate in refractory synovitis of the knee: Experience of 2 reference hospitals","authors":"I. Bolívar Roldán ,&nbsp;Ana Moreno Ballesteros ,&nbsp;C. Martínez Chinchilla ,&nbsp;A. Jiménez-Heffernan ,&nbsp;M.C. Calvo Morón","doi":"10.1016/j.remnie.2024.500052","DOIUrl":"10.1016/j.remnie.2024.500052","url":null,"abstract":"<div><h3>Introduction</h3><div>To describe the therapeutic efficacy of radiosynoviorthesis with [<sup>90</sup>Y]Yttrium citrate (<sup>90</sup>Y), in patients with chronic knee synovitis refractory to systemic treatments and/or infiltrations, correlating the results with the different etiologies and degenerative changes that they showed, in order to optimize the indication of the technique.</div></div><div><h3>Material and methods</h3><div>Observational retrospective study with 32 patients (22 men and 10 women) and 34 knees, with refractory chronic knee synovitis, who underwent radiosynoviorthesis between January 2013 and December 2022. Its efficacy was described and analyzed by the subjective improvement referred by the patients and its relationship with the existing etiologies and radiological degenerative changes, expressed by the Kellgren-Lawrence (K-L) scale.</div></div><div><h3>Results</h3><div>A statistically significant subjective improvement was observed in 70.6% of the cases (<em>p</em> &lt; 0.001). There were 92.3% of cases with absent, doubtful or mild degenerative changes (K-L 0-2) who improved, while only 50% with moderate or severe changes (K-L 3-4) improved, showing statistically significant differences (<em>p</em> = 0.03). Among patients with chronic inflammatory origin of synovitis (spondyloarthropathies and rheumatoid arthritis), 80% improved, while in those with osteoarthritis (degenerative) origin, only 25% improved with statistically significant differences (p = 0.006).</div></div><div><h3>Conclusions</h3><div>Radiosynoviorthesis with <sup>90</sup>Y is an effective treatment in patients with knee refractory chronic synovitis, especially in the presence of mil degenerative joint changes and chronic inflammatory origin. We must ensure the appropiate selection of patients according to these criteria.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500052"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A huge adrenocortical carcinoma mimicking liver mass 巨大肾上腺皮质癌模仿肝脏肿块。
Pub Date : 2024-11-01 DOI: 10.1016/j.remnie.2024.500060
N. Aydinbelge-Dizdar , D. Cayir , S. Canlar , E.N. Celik , E. Cakal
{"title":"A huge adrenocortical carcinoma mimicking liver mass","authors":"N. Aydinbelge-Dizdar ,&nbsp;D. Cayir ,&nbsp;S. Canlar ,&nbsp;E.N. Celik ,&nbsp;E. Cakal","doi":"10.1016/j.remnie.2024.500060","DOIUrl":"10.1016/j.remnie.2024.500060","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500060"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of [18F]FDG PET/CT in the evaluation of inflammatory breast cancer: A case report 18F]FDG PET/CT 在炎性乳腺癌评估中的作用:病例报告。
Pub Date : 2024-11-01 DOI: 10.1016/j.remnie.2024.500057
B. Hervás-Sanz , I.E. Sánchez-Rodríguez , A. Fernández-Ortega , P. Perlaza-Jiménez , M. Cortés-Romera , J. Suils-Ramón
{"title":"Role of [18F]FDG PET/CT in the evaluation of inflammatory breast cancer: A case report","authors":"B. Hervás-Sanz ,&nbsp;I.E. Sánchez-Rodríguez ,&nbsp;A. Fernández-Ortega ,&nbsp;P. Perlaza-Jiménez ,&nbsp;M. Cortés-Romera ,&nbsp;J. Suils-Ramón","doi":"10.1016/j.remnie.2024.500057","DOIUrl":"10.1016/j.remnie.2024.500057","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500057"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Solitary adrenal metastasis of breast cancer on [68Ga]Ga-DOTA-TATE PET/CT 68Ga]Ga-DOTA-TATE正电子发射计算机断层扫描显示的乳腺癌孤立肾上腺转移。
Pub Date : 2024-11-01 DOI: 10.1016/j.remnie.2024.500061
N. Filizoglu , S. Ozguven , F. Dede , H.T. Turoglu , T.Y. Erdil
{"title":"Solitary adrenal metastasis of breast cancer on [68Ga]Ga-DOTA-TATE PET/CT","authors":"N. Filizoglu ,&nbsp;S. Ozguven ,&nbsp;F. Dede ,&nbsp;H.T. Turoglu ,&nbsp;T.Y. Erdil","doi":"10.1016/j.remnie.2024.500061","DOIUrl":"10.1016/j.remnie.2024.500061","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500061"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular [18F]F-FDG PET/MRI in the diagnosis of acute cardiomyopathy inflammatory 心血管[18F]F-FDG PET/MRI在急性心肌炎诊断中的应用。
Pub Date : 2024-11-01 DOI: 10.1016/j.remnie.2024.500038
J.R. Garcia, R. Olivero, M. Panelo, L. Mont, L. Pinilla, M.E. Riera, A. Maceira
{"title":"Cardiovascular [18F]F-FDG PET/MRI in the diagnosis of acute cardiomyopathy inflammatory","authors":"J.R. Garcia,&nbsp;R. Olivero,&nbsp;M. Panelo,&nbsp;L. Mont,&nbsp;L. Pinilla,&nbsp;M.E. Riera,&nbsp;A. Maceira","doi":"10.1016/j.remnie.2024.500038","DOIUrl":"10.1016/j.remnie.2024.500038","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500038"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determination of fundic accommodation in gastric emptying scintigraphy. Evaluation of its clinical usefulness 胃排空闪烁成像中胃底容积的测定。评估其临床实用性。
Pub Date : 2024-11-01 DOI: 10.1016/j.remnie.2024.500051
J.R. Infante, A. Utrera, A. Baena, R. Barco, A. Martínez, C. Durán, P. Jiménez, J. Serrano

Aim

Gastric emptying scintigraphy is used to assess patients with symptoms of dyspepsia or gastroparesis. An alteration of fundus accommodation may explain these symptoms. The aim of this study was to determine the accommodation in gastric emptying scintigraphy studies performed in our institution.

Material and methods

50 patients (43 children) referred for gastric emptying assessment were evaluated. After fasting for 8 h, and following international guidelines, egg labeling was performed with 37 mBq of [99mTc]Tc-DTPA and administration of standardized food. Areas of interest were defined in the stomach at different times, and the corresponding retention percentages were calculated. Considering the image at time zero, gastric accommodation was qualitatively and quantitatively assessed, calculating the ratio between proximal stomach counts and total counts.

Results

Of the 50 patients studied, 32 had normal emptying, 10 had slowed emptying and 8 had accelerated emptying. Within the group of patients with normal emptying, 8 had altered accommodation (25%) and another 8 in the group with abnormal emptying (44%). Applying the ROC curve analysis to quantitative values, the most appropriate cut-off value was 0.785 with p < 0.001, sensitivity 82.4% and specificity 100%.

Conclusion

Gastric emptying scintigraphy in addition to determining motility, made it possible to assess both qualitatively and quantitatively the distribution of the radiotracer in the stomach and thus, indirectly, the accommodation in the fundus. It provided added diagnostic information in a simple manner, without protocol changes and allowing more specific treatments to be assessed.
目的:胃排空闪烁扫描可用于评估有消化不良或胃痉挛症状的患者。眼底容受性的改变可能是这些症状的原因。本研究旨在确定在我院进行的胃排空闪烁成像研究中的胃底容受性。禁食 8 小时后,按照国际指南,使用 37 m Bq 的 [99mTc]Tc-DTPA 和标准食物进行鸡蛋标记。在不同时间确定胃中的感兴趣区,并计算相应的滞留率。根据零时的图像,对胃容纳量进行定性和定量评估,计算近端胃计数与总计数的比率:在研究的 50 名患者中,32 人排空正常,10 人排空减慢,8 人排空加速。在排空正常的患者组中,有 8 人的胃容纳能力发生改变(25%),另有 8 人排空异常(44%)。通过对定量值进行 ROC 曲线分析,最合适的临界值为 0.785,P 为 0.785:胃排空闪烁扫描除了能确定胃的蠕动外,还能定性和定量评估放射性示踪剂在胃中的分布,从而间接评估胃底的容纳情况。它以简单的方式提供了更多的诊断信息,无需更改方案,还能评估更多具体的治疗方法。
{"title":"Determination of fundic accommodation in gastric emptying scintigraphy. Evaluation of its clinical usefulness","authors":"J.R. Infante,&nbsp;A. Utrera,&nbsp;A. Baena,&nbsp;R. Barco,&nbsp;A. Martínez,&nbsp;C. Durán,&nbsp;P. Jiménez,&nbsp;J. Serrano","doi":"10.1016/j.remnie.2024.500051","DOIUrl":"10.1016/j.remnie.2024.500051","url":null,"abstract":"<div><h3>Aim</h3><div>Gastric emptying scintigraphy is used to assess patients with symptoms of dyspepsia or gastroparesis. An alteration of fundus accommodation may explain these symptoms. The aim of this study was to determine the accommodation in gastric emptying scintigraphy studies performed in our institution.</div></div><div><h3>Material and methods</h3><div>50 patients (43 children) referred for gastric emptying assessment were evaluated. After fasting for 8 h, and following international guidelines, egg labeling was performed with 37 mBq of [<sup>99</sup>mTc]Tc-DTPA and administration of standardized food. Areas of interest were defined in the stomach at different times, and the corresponding retention percentages were calculated. Considering the image at time zero, gastric accommodation was qualitatively and quantitatively assessed, calculating the ratio between proximal stomach counts and total counts.</div></div><div><h3>Results</h3><div>Of the 50 patients studied, 32 had normal emptying, 10 had slowed emptying and 8 had accelerated emptying. Within the group of patients with normal emptying, 8 had altered accommodation (25%) and another 8 in the group with abnormal emptying (44%). Applying the ROC curve analysis to quantitative values, the most appropriate cut-off value was 0.785 with <em>p</em> &lt; 0.001, sensitivity 82.4% and specificity 100%.</div></div><div><h3>Conclusion</h3><div>Gastric emptying scintigraphy in addition to determining motility, made it possible to assess both qualitatively and quantitatively the distribution of the radiotracer in the stomach and thus, indirectly, the accommodation in the fundus. It provided added diagnostic information in a simple manner, without protocol changes and allowing more specific treatments to be assessed.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500051"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET/CT for the prediction of biochemical recurrence in prostate cancer 治疗前[68Ga]Ga-PSMA PET/CT 预测前列腺癌生化复发的原发肿瘤异质性
Pub Date : 2024-11-01 DOI: 10.1016/j.remnie.2024.500032
Seda Gülbahar Ateş , Bedriye Büşra Demirel , Esra Kekilli , Erdem Öztürk , Gülin Uçmak

Purpose

The aim of this study is to research the value of the texture analysis of primary tumors in pre-treatment [68Ga]Ga-PSMA PET in the prediction of the development of biochemical recurrence (BCR) in prostate cancer patients who underwent definitive therapies.

Methods

51 patients with prostate adenocarcinoma who had a pre-treatment [68Ga]Ga-PSMA-11 PET/CT and underwent definitive radiotherapy (RT) or radical prostatectomy (RP) were included in the study. Demographics, clinicopathologic features, the presence of BCR, and the last follow-up date of patients were recorded. Textural and conventional PET parameters (maximum standardized uptake value (SUVmax), total lesion-PSMA (TL-PSMA), and PSMA-tumor volume (PSMA-TV)) were obtained from PET/CT images using LifeX program. Parameters were grouped using the Youden index in ROC analysis. Factors predicting the BCR were determined using Cox regression analyses.

Results

29 (56.9%) patients have received primary curative RT, while the remaining 22 (43.1%) patients have undergone RP. 5 (22.7%) patients with RP and 3 (10.3%) patients with curative RT have developed BCR during the follow-up. INTENSITY-BASED-minimum grey level (P = .050), GLCM-sum variance (P = .019), and GLCM-cluster prominence (P = .050) were associated with BCR in univariate analysis. INTENSITY-BASED-minimum grey level (P = .009) and GLCM-sum variance (P = .004) were found as independent predictors of BCR in the multivariate analysis.

Conclusion

Tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET is associated with a high risk of BCR in PCa patients who underwent definitive therapies.
目的:本研究旨在研究治疗前[68Ga]Ga-PSMA PET中原发肿瘤的纹理分析在预测接受明确治疗的前列腺癌患者生化复发(BCR)发展中的价值。方法:本研究纳入了51例接受治疗前[68Ga]Ga-PSMA-11 PET/CT检查并接受明确放疗(RT)或根治性前列腺切除术(RP)的前列腺腺癌患者。研究人员记录了患者的人口统计学特征、临床病理学特征、是否存在 BCR 以及最后一次随访日期。使用LifeX程序从PET/CT图像中获取纹理参数和常规PET参数(最大标准化摄取值(SUVmax)、总病灶-PSMA(TL-PSMA)和PSMA-肿瘤体积(PSMA-TV))。在 ROC 分析中使用尤登指数对参数进行分组。结果:29 例(56.9%)患者接受了初治性 RT,其余 22 例(43.1%)患者接受了 RP。在随访期间,5 例(22.7%)RP 患者和 3 例(10.3%)根治性 RT 患者出现了 BCR。INTENSITY-BASED-minimum grey level(P = 0.050)、GLCM-sum variance(P = 0.019)和 GLCM-cluster prominence(P = 0.050)在单变量分析中与 BCR 相关。在多变量分析中发现,基于强度的最小灰度(p = 0.009)和 GLCM 总方差(p = 0.004)是 BCR 的独立预测因素:结论:治疗前[68Ga]Ga-PSMA PET显示的肿瘤异质性与接受明确疗法的PCa患者发生BCR的高风险有关。
{"title":"Primary tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET/CT for the prediction of biochemical recurrence in prostate cancer","authors":"Seda Gülbahar Ateş ,&nbsp;Bedriye Büşra Demirel ,&nbsp;Esra Kekilli ,&nbsp;Erdem Öztürk ,&nbsp;Gülin Uçmak","doi":"10.1016/j.remnie.2024.500032","DOIUrl":"10.1016/j.remnie.2024.500032","url":null,"abstract":"<div><h3>Purpose</h3><div>The aim of this study is to research the value of the texture analysis of primary tumors in pre-treatment [68Ga]Ga-PSMA PET in the prediction of the development of biochemical recurrence (BCR) in prostate cancer patients who underwent definitive therapies.</div></div><div><h3>Methods</h3><div>51 patients with prostate adenocarcinoma who had a pre-treatment [68Ga]Ga-PSMA-11 PET/CT and underwent definitive radiotherapy (RT) or radical prostatectomy (RP) were included in the study. Demographics, clinicopathologic features, the presence of BCR, and the last follow-up date of patients were recorded. Textural and conventional PET parameters (maximum standardized uptake value (SUVmax), total lesion-PSMA (TL-PSMA), and PSMA-tumor volume (PSMA-TV)) were obtained from PET/CT images using LifeX program. Parameters were grouped using the Youden index in ROC analysis. Factors predicting the BCR were determined using Cox regression analyses.</div></div><div><h3>Results</h3><div>29 (56.9%) patients have received primary curative RT, while the remaining 22 (43.1%) patients have undergone RP. 5 (22.7%) patients with RP and 3 (10.3%) patients with curative RT have developed BCR during the follow-up. INTENSITY-BASED-minimum grey level (<em>P</em> <!-->=<!--> <!-->.050), GLCM-sum variance (<em>P</em> <!-->=<!--> <!-->.019), and GLCM-cluster prominence (<em>P</em> <!-->=<!--> <!-->.050) were associated with BCR in univariate analysis. INTENSITY-BASED-minimum grey level (<em>P</em> <!-->=<!--> <!-->.009) and GLCM-sum variance (<em>P</em> <!-->=<!--> <!-->.004) were found as independent predictors of BCR in the multivariate analysis.</div></div><div><h3>Conclusion</h3><div>Tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET is associated with a high risk of BCR in PCa patients who underwent definitive therapies.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500032"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Supernumerary kidney fused to the isthmus of a horseshoe kidney, with subsequent nephroblastoma, identified with dynamic renal scintigraphy 通过动态肾脏闪烁扫描发现与马蹄肾峡部融合的赘生肾脏,继发肾母细胞瘤。
Pub Date : 2024-11-01 DOI: 10.1016/j.remnie.2024.500058
S. Bondia-Bescós , L.J. Pregil , L. Biassoni
{"title":"Supernumerary kidney fused to the isthmus of a horseshoe kidney, with subsequent nephroblastoma, identified with dynamic renal scintigraphy","authors":"S. Bondia-Bescós ,&nbsp;L.J. Pregil ,&nbsp;L. Biassoni","doi":"10.1016/j.remnie.2024.500058","DOIUrl":"10.1016/j.remnie.2024.500058","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500058"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between 99mTc-PSMA SPECT/CT imaging and prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels post-endocrine therapy in patients with prostate cancer and bone metastases 前列腺癌骨转移患者内分泌治疗后 99mTc-PSMA SPECT/CT 成像与前列腺特异性抗原 (PSA) 和碱性磷酸酶 (ALP) 水平之间的关系。
Pub Date : 2024-11-01 DOI: 10.1016/j.remnie.2024.500054
X. Ruan , Y. Gao

Aim

To investigate the association between positive lesions detected by 99mTc-PSMA SPECT/CT and blood levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) in patients with prostate cancer (PCa) and bone metastasis undergoing endocrine therapy.

Methods

A retrospective analysis was performed on 43 patients diagnosed with PCa bone metastasis who underwent endocrine therapy. PSA, ALP, whole body bone imaging and 99mTc-PSMA SPECT/CT imaging were collected from all patients (Among them, 17 cases were re-examined 99mTc-PSMA SPECT/CT imaging). According to the results of the first 99mTc-PSMA SPECT/CT imaging for detecting bone metastasis, all cases were divided into two groups: positive group and negative group. The relationship between 99mTc-PSMA imaging and PSA and ALP was analyzed by ROC curve. Fisher exact probability method was used to examine the changes in imaging radioactivity uptake, PSA, and ALP levels in 17 patients after treatment, and P < 0.05 was statistically significant.

Results

All 43 patients had different degrees of radioactive concentrations on whole-body bone imaging. The first 99mTc-PSMA SPECT/CT imaging showed positive bone metastases in 31 cases and negative bone metastases in 12 cases. ROC curve analysis of PSA and ALP, AUC were 0.778 and 0.770, respectively. When PSA > 1.13 ng/mL, 99mTc-PSMA SPECT/CT imaging diagnostic sensitivity was 93.55%, and specificity was 66.67%. When ALP was >86U/L, the diagnostic sensitivity of 99mTc-PSMA SPECT/CT imaging was 64.52%, and the specificity was 83.33%. In 17 cases, the PSA level decreased in 7 and increased in 10. There were 10 cases of increased ALP and 7 cases of decreased ALP levels. In the second 99mTc-PSMA imaging lesion, there were 9 cases with decreased or no uptake, and 8 cases with increased uptake or number of lesions. The changes in 99mTc-PSMA uptake by Fisher’s exact probability method were statistically significant (P < 0.05, P = 0.006, and P = 0.006, respectively), and ALP level was not statistically significant (P = 0.563).

Conclusion

99mTc-PSMA SPECT/CT imaging can detect PCa bone metastases, which are related to PSA levels. When PSA > 1.13 ng/mL, the sensitivity of diagnosis and detection of positive bone metastases is higher, and when ALP is >86U/L, 99mTc-PSMA imaging has higher specificity.
目的:研究接受内分泌治疗的前列腺癌(PCa)骨转移患者中,99m锝-PSMA SPECT/CT 检测到的阳性病灶与血液中前列腺特异性抗原(PSA)和碱性磷酸酶(ALP)水平之间的关系:对43名接受内分泌治疗的PCa骨转移患者进行回顾性分析。收集了所有患者的 PSA、ALP、全身骨成像和 99mTc-PSMA SPECT/CT 成像(其中 17 例患者再次接受了 99mTc-PSMA SPECT/CT 成像检查)。根据首次 99mTc-PSMA SPECT/CT 成像检测骨转移的结果,将所有病例分为两组:阳性组和阴性组。采用 ROC 曲线分析 99mTc-PSMA 成像与 PSA 和 ALP 的关系。采用费雪精确概率法检测 17 例患者治疗后影像学放射性摄取、PSA 和 ALP 水平的变化,P 结果:所有 43 名患者的全身骨成像均有不同程度的放射性浓度。首次 99mTc-PSMA SPECT/CT 成像显示 31 例骨转移阳性,12 例骨转移阴性。PSA 和 ALP 的 ROC 曲线分析,AUC 分别为 0.778 和 0.770。当 PSA > 1.13 ng/mL 时,99m锝-PSMA SPECT/CT 成像诊断敏感性为 93.55%,特异性为 66.67%。当 ALP >86U/L 时,99m锝-PSMA SPECT/CT 成像的诊断敏感性为 64.52%,特异性为 83.33%。17 例患者中,7 例 PSA 水平下降,10 例上升。10例ALP水平升高,7例ALP水平降低。在第二次99m锝-PSMA成像病灶中,有9例摄取减少或无摄取,8例摄取增加或病灶数量增加。99m锝-PSMA摄取量的变化以Fisher精确概率法计算具有统计学意义(P 结论:99m锝-PSMA SPECT/CT成像可发现PCa骨转移,而PCa骨转移与PSA水平有关。当 PSA > 1.13 ng/mL 时,诊断和检测阳性骨转移灶的敏感性更高;当 ALP > 86U/L 时,99m锝-PSMA 成像具有更高的特异性。
{"title":"Association between 99mTc-PSMA SPECT/CT imaging and prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels post-endocrine therapy in patients with prostate cancer and bone metastases","authors":"X. Ruan ,&nbsp;Y. Gao","doi":"10.1016/j.remnie.2024.500054","DOIUrl":"10.1016/j.remnie.2024.500054","url":null,"abstract":"<div><h3>Aim</h3><div>To investigate the association between positive lesions detected by 99mTc-PSMA SPECT/CT and blood levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) in patients with prostate cancer (PCa) and bone metastasis undergoing endocrine therapy.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed on 43 patients diagnosed with PCa bone metastasis who underwent endocrine therapy. PSA, ALP, whole body bone imaging and 99mTc-PSMA SPECT/CT imaging were collected from all patients (Among them, 17 cases were re-examined 99mTc-PSMA SPECT/CT imaging). According to the results of the first 99mTc-PSMA SPECT/CT imaging for detecting bone metastasis, all cases were divided into two groups: positive group and negative group. The relationship between 99mTc-PSMA imaging and PSA and ALP was analyzed by ROC curve. Fisher exact probability method was used to examine the changes in imaging radioactivity uptake, PSA, and ALP levels in 17 patients after treatment, and <em>P</em> &lt; 0.05 was statistically significant.</div></div><div><h3>Results</h3><div>All 43 patients had different degrees of radioactive concentrations on whole-body bone imaging. The first 99mTc-PSMA SPECT/CT imaging showed positive bone metastases in 31 cases and negative bone metastases in 12 cases. ROC curve analysis of PSA and ALP, AUC were 0.778 and 0.770, respectively. When PSA &gt; 1.13 ng/mL, 99mTc-PSMA SPECT/CT imaging diagnostic sensitivity was 93.55%, and specificity was 66.67%. When ALP was &gt;86U/L, the diagnostic sensitivity of 99mTc-PSMA SPECT/CT imaging was 64.52%, and the specificity was 83.33%. In 17 cases, the PSA level decreased in 7 and increased in 10. There were 10 cases of increased ALP and 7 cases of decreased ALP levels. In the second 99mTc-PSMA imaging lesion, there were 9 cases with decreased or no uptake, and 8 cases with increased uptake or number of lesions. The changes in 99mTc-PSMA uptake by Fisher’s exact probability method were statistically significant (<em>P</em> &lt; 0.05, <em>P</em> = 0.006, and <em>P</em> = 0.006, respectively), and ALP level was not statistically significant (<em>P</em> = 0.563).</div></div><div><h3>Conclusion</h3><div>99mTc-PSMA SPECT/CT imaging can detect PCa bone metastases, which are related to PSA levels. When PSA &gt; 1.13 ng/mL, the sensitivity of diagnosis and detection of positive bone metastases is higher, and when ALP is &gt;86U/L, 99mTc-PSMA imaging has higher specificity.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500054"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low dose radioactive iodine ablation therapy (1.11GBq) for differentiated thyroid cancer in Western Turkey 土耳其西部分化型甲状腺癌的低剂量放射性碘消融治疗(1.11GBq)。
Pub Date : 2024-11-01 DOI: 10.1016/j.remnie.2024.500055
B. Karasah Erkek , H. Sariyildiz Gumusgoz , A. Oral , B. Yazici , A. Akgun

Objective

Ablation therapy is employed in low-risk differentiated thyroid cancer (DTC) cases to facilitate patient monitoring by reducing thyroglobulin (Tg) levels to measurable levels below after surgery by eliminating residual thyroid tissue. However, there is still uncertainty about the minimum activity dose required for effective ablation. Opting for low-dose [131I]-NaI for ablation offers several advantages for both patients and healthcare services. Particularly in this tumor group with a high life expectancy (approximately 90–95 % at 10 years), [131I]-NaI treatment should not pose a risk to the patient's post-treatment life and should not compromise their quality of life. However, there is a need for a well-defined identification of factors predicting successful ablation.

Methods

Clinical data, laboratory findings, and imaging tests of 287 patients with low-dose 1110 MBq (30 mCi) [131I]-NaI ablation therapy for DTC were retrospectively reviewed. Post-ablation imaging and laboratory findings categorized ablation success/failure. The successful ablation group was determined according to the excellent response criteria outlined in ATA criteria. Relationships between clinical, pathological findings, biochemical common variables, and treatment failure were analyzed.

Results

An excellent response was achieved in 77% of the entire group according to ATA criteria post-ablation. Male gender and high Tg levels on the day of ablation (Tg cut-off: 10 ng/mL and 5.35 ng/mL) were associated with unsuccessful ablation.

Conclusions

Our results indicate that a 1110MBq (30mCi) ablation dose is sufficient to achieve an excellent response in most low-risk DTC cases 6–12 months later. When selecting the dose for ablation, besides the histological markers mentioned in guidelines and age, we observed that stimulated Tg values and gender may be important in predicting ablation success.
目的:在低风险分化型甲状腺癌(DTC)病例中采用消融治疗,通过消除残留甲状腺组织,将甲状腺球蛋白(Tg)水平降至术后可测量水平以下,从而便于对患者进行监测。然而,有效消融所需的最小活性剂量仍不确定。选择低剂量[131I]-NaI进行消融为患者和医疗服务提供了多项优势。特别是对于预期寿命较长(10 年后约为 90-95%)的肿瘤患者,[131I]-NaI 治疗不应对患者治疗后的生活构成风险,也不会影响他们的生活质量。然而,需要明确确定预测成功消融的因素:方法:回顾性研究了287例接受低剂量1110 MBq(30 mCi)[131I]-NaI消融治疗的DTC患者的临床数据、实验室检查结果和影像学检查。消融后的影像学和实验室检查结果分为消融成功/失败两类。成功消融组是根据 ATA 标准中列出的极佳反应标准确定的。分析了临床、病理结果、生化常见变量与治疗失败之间的关系:结果:根据 ATA 标准,77% 的患者在消融术后获得了极佳反应。男性性别和消融当天的高 Tg 水平(Tg 临界值:10 纳克/毫升和 5.35 纳克/毫升)与消融失败有关:我们的研究结果表明,1110MBq(30mCi)的消融剂量足以使大多数低风险 DTC 病例在 6-12 个月后获得极佳反应。在选择消融剂量时,除了指南中提到的组织学标志物和年龄外,我们还发现刺激 Tg 值和性别可能是预测消融成功的重要因素。
{"title":"Low dose radioactive iodine ablation therapy (1.11GBq) for differentiated thyroid cancer in Western Turkey","authors":"B. Karasah Erkek ,&nbsp;H. Sariyildiz Gumusgoz ,&nbsp;A. Oral ,&nbsp;B. Yazici ,&nbsp;A. Akgun","doi":"10.1016/j.remnie.2024.500055","DOIUrl":"10.1016/j.remnie.2024.500055","url":null,"abstract":"<div><h3>Objective</h3><div>Ablation therapy is employed in low-risk differentiated thyroid cancer (DTC) cases to facilitate patient monitoring by reducing thyroglobulin (Tg) levels to measurable levels below after surgery by eliminating residual thyroid tissue. However, there is still uncertainty about the minimum activity dose required for effective ablation. Opting for low-dose [131I]-NaI for ablation offers several advantages for both patients and healthcare services. Particularly in this tumor group with a high life expectancy (approximately 90–95 % at 10 years), [131I]-NaI treatment should not pose a risk to the patient's post-treatment life and should not compromise their quality of life. However, there is a need for a well-defined identification of factors predicting successful ablation.</div></div><div><h3>Methods</h3><div>Clinical data, laboratory findings, and imaging tests of 287 patients with low-dose 1110 MBq (30 mCi) [131I]-NaI ablation therapy for DTC were retrospectively reviewed. Post-ablation imaging and laboratory findings categorized ablation success/failure. The successful ablation group was determined according to the excellent response criteria outlined in ATA criteria. Relationships between clinical, pathological findings, biochemical common variables, and treatment failure were analyzed.</div></div><div><h3>Results</h3><div>An excellent response was achieved in 77% of the entire group according to ATA criteria post-ablation. Male gender and high Tg levels on the day of ablation (Tg cut-off: 10 ng/mL and 5.35 ng/mL) were associated with unsuccessful ablation.</div></div><div><h3>Conclusions</h3><div>Our results indicate that a 1110MBq (30mCi) ablation dose is sufficient to achieve an excellent response in most low-risk DTC cases 6–12 months later. When selecting the dose for ablation, besides the histological markers mentioned in guidelines and age, we observed that stimulated Tg values and gender may be important in predicting ablation success.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500055"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista espanola de medicina nuclear e imagen molecular
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1